SCT650C not checked
Sinocelltech · Recombinant anti-IL-17A antibody
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hidradenitis Suppurativa (HS)
- Main trialPhase 2
- “The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SCT650C in patients with Moderate to Severe Hidradenitis Suppurativa”In the company’s words, NCT07244510 on ClinicalTrials.gov
- Other names
- Recombinant anti-IL-17A antibody
Other drugs for Hidradenitis Suppurativa (HS)
- RuxolitinibIncyte · Novartis · Phase 3
- BimekizumabUCB Biopharma SRL · Phase 3
- PovorcitinibIncyte Corporation · Phase 3
- LutikizumabAbbVie · Phase 3
- RemibrutinibNovartis · Phase 3
- BFB759Bluefin Biomedicine, Inc. · Phase 2/3
Coming up1
- 12 Mar 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 12 Mar 2027 | Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa | |
| Phase 2Unknown | 1 Jul 2026 | Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis | |
| Phase 1Unknown | Nov 2023 | Evaluate the Safety and Tolerability of SCT650C in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026